Comparison
3p Syndrome C4706503 vs 21 Hydroxylase Deficient Congenital Adrenal Hyperplasia C2936858
Clinical comparison between 3P Syndrome and 21 Hydroxylase Deficient Congenital Adrenal Hyperplasia for differential diagnosis and treatment planning.
3p Syndrome C4706503
A rare chromosomal disorder involving deletion of genetic material from chromosome 3. It causes distinctive facial features, growth delays, and intellectual disability. Care involves managing developmental and medical complications.
21 Hydroxylase Deficient Congenital Adrenal Hyperplasia C2936858
An inherited disorder affecting adrenal hormone production, causing cortisol deficiency and other hormonal imbalances. Features may include ambiguous genitalia, salt-wasting crises, and growth issues. Treated with lifelong hormone replacement therapy.
6 comparison axes
Onset
3p Syndrome C4706503
0-0
21 Hydroxylase Deficient Congenital Adrenal Hyperplasia C2936858
0-null
Onset patterns differ
Severity
3p Syndrome C4706503
severe
21 Hydroxylase Deficient Congenital Adrenal Hyperplasia C2936858
severe
Different severity levels
Chronic
3p Syndrome C4706503
Chronic
21 Hydroxylase Deficient Congenital Adrenal Hyperplasia C2936858
Chronic
Differing course
Communicable
3p Syndrome C4706503
No
21 Hydroxylase Deficient Congenital Adrenal Hyperplasia C2936858
No
Different transmission
Body System
3p Syndrome C4706503
congenital
21 Hydroxylase Deficient Congenital Adrenal Hyperplasia C2936858
endocrine
Same/different system
Category
3p Syndrome C4706503
genetic
21 Hydroxylase Deficient Congenital Adrenal Hyperplasia C2936858
endocrine
Different category
Bottom line
3p-syndrome-C4706503 and 21-hydroxylase-deficient-congenital-adrenal-hyperplasia-C2936858 differ in etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 3p Syndrome C4706503 | 21 Hydroxylase Deficient Congenital Adrenal Hyperplasia C2936858 | Discriminating power |
|---|---|---|---|
| Developmental profile | Intellectual disability and developmental delay are characteristic. | Development is not primarily defined by chromosomal deletion; effects vary with hormone control. | High |
| Genital and adrenal features | Not primarily an adrenal hormone disorder; genital findings are not defining. | May include atypical genitalia, cortisol deficiency, or salt-wasting crisis. | High |
| Facial and growth pattern | Distinctive facial features and growth delay may occur. | Growth can be affected, but facial dysmorphism is not the core feature. | Moderate |
When to favor each condition
Choose 3p Syndrome C4706503 when
Congenital dysmorphism with developmental delay
This pattern supports evaluation for a chromosomal deletion rather than primary adrenal disease.
Moderate
Chromosomal test shows 3p deletion
A confirmed relevant deletion supports the chromosomal diagnosis.
High
No adrenal crisis or steroid abnormality
Absence of endocrine findings makes CAH less likely, but does not prove 3p syndrome.
Low
Choose 21 Hydroxylase Deficient Congenital Adrenal Hyperplasia C2936858 when
Newborn with atypical genitalia or salt-wasting illness
These features warrant urgent endocrine evaluation for CAH.
High
Biochemical evidence of 21-hydroxylase deficiency
Abnormal adrenal steroid results support CAH, with genetics used for confirmation.
High
Family history of CAH or related carrier status
Inheritance pattern increases suspicion but is not diagnostic alone.
Moderate
How key tests differ
| Test | 3p Syndrome C4706503 | 21 Hydroxylase Deficient Congenital Adrenal Hyperplasia C2936858 | Interpretation |
|---|---|---|---|
| Chromosomal microarray or karyotype | May identify deletion involving chromosome 3p. | Not expected to diagnose 21-hydroxylase deficiency. | A chromosomal result supports 3p syndrome only when clinically correlated. |
| Adrenal steroid profile, including 17-hydroxyprogesterone | No characteristic CAH pattern is established. | May show a pattern consistent with 21-hydroxylase deficiency. | An abnormal result suggests CAH but requires clinician interpretation and confirmation. |
| CYP21A2 genetic testing | Not the primary diagnostic test. | Pathogenic variants can confirm the inherited disorder. | Genetics helps distinguish CAH from chromosomal conditions. |
Prognosis comparison
3p Syndrome C4706503
- Outcome
- Often chronic developmental and medical needs; exact survival cannot be stated from these data.
- Factors
- Deletion extent, associated anomalies, developmental support, and complications.
21 Hydroxylase Deficient Congenital Adrenal Hyperplasia C2936858
- Outcome
- Chronic endocrine condition; outcomes depend strongly on early recognition and hormone management.
- Factors
- Salt-wasting risk, treatment adherence, growth, puberty, and adrenal crisis prevention.
Time frame: Both may be recognized in infancy and require long-term follow-up.
Prognosis is individualized; these sources do not establish mortality or universal outcomes.
Complications comparison
| Complication | Presentation |
|---|---|
| Acute metabolic crisis | Not a defining complication in the supplied description. Salt-wasting crisis can be life-threatening if untreated. Suspected adrenal crisis needs urgent clinical care. |
| Neurodevelopment | Intellectual disability and developmental complications are central. Neurodevelopment depends on individual course and hormone management. Support needs should be assessed individually. |
| Growth and puberty | Growth delay may occur. Growth and puberty can be affected by hormone imbalance or treatment. Exact outcomes and treatment doses are not established here. |
Patient education highlights
- HighDifferent causes
3p syndrome is chromosomal, while this CAH type is an inherited adrenal hormone disorder.
- HighUrgent warning signs
Poor feeding, vomiting, dehydration, or collapse in a suspected CAH infant needs emergency care.
- MediumLong-term care
Both conditions may need coordinated specialist follow-up; CAH generally requires lifelong hormone replacement.